Ilonov is a preclinical stage biotech developing first-in-class biologics against chronic metabolic diseases, harvesting the potential of muscle secretome to regulate metabolism, a novel & unexplored approach. Our biotherapy specifically preserves & stimulates pancreatic beta cell function by restoring the integrity of the extracellular matrix of the islet niche. Discovered in human muscle post-exercise, our asset has already proven safety & efficacy in preclinical T1D & T2D models in vivo.